In conclusion, the incidence of neutropenia in this study indicated that advanced PC patients with UGT1A1-DV tolerate irinotecan administered at the initial dose of  ≤ 120 mg/m2. This evidence concerns the gene UGT1A1 and pachyonychia congenita.